DocDollars

Kala Pharmaceuticals, Inc.

MA · United States · Reporting entity ID 100000486818

Total reported 2019–2025
$7.59M
#578 of 2,960 reporting companies — 0% of all reported industry payments
$3.52M in general payments across 36,765 records, plus $4.07M in research funding across 748 records.

How it breaks down

General payments $3,515,212
Research funding $4,070,644

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Kala Pharmaceuticals, Inc. reported $7.59M to US doctors and teaching hospitals from 2019 to 2025, ranking #578 of 2,960 reporting companies. 54% of that was research funding and 46% general payments such as consulting, speaking, food and travel. 36,765 general payment records and 748 research records were filed.

Common questions about Kala Pharmaceuticals, Inc.

How much has Kala Pharmaceuticals, Inc. paid US doctors?

Kala Pharmaceuticals, Inc. reported $7,585,856 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $3,515,212 in general payments, $4,070,644 in research funding.

How does Kala Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #578 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Kala Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.